[The overuse of antibiotics has] become a real problem: antibiotic-resistant pneumonia rates currently exceed 50% in the U.S. Clearly, there’s a huge need for new therapies.
[GlaxoSmithKline] recently decided to depart from its traditional approach to product development, by announcing a bold joint venture with Verily Life Sciences…to create the first generation of bioelectronic medicines for chronic diseases.
Cempra is one company focused on finding a solution. The company’s lead compound is called solithromycin, and it’s currently pending FDA approval as a treatment for community-acquired bacterial pneumonia, or CABP.
…
Developing an effective vaccine to prevent Zika virus infection could take years. In the meantime, efforts to cull populations of the infamous Aedes aegypti mosquito…may get a boost from Intrexon.
[L]ast September it made a bold $146.4 million acquisition of Oxitec and its genetically engineered self-limiting mosquito technology…It almost sounds too easy, but data from a pilot program in the city of Piracicaba, Brazil, are highly encouraging.…
Share this article
…
While this moonshot effort is still in its infancy…this foray into bioelectronic medicine is well worth checking out….
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. Read full, original post: 3 Bold Bets on the Future of Biotechnology
